LENSAR (NASDAQ:LNSR) Posts Quarterly Earnings Results, Beats Expectations By $0.26 EPS

Key Points

• LENSAR reported quarterly EPS of $0.10, beating the consensus estimate of a $0.16 loss by $0.26. Revenue increased 18% year over year to $16.5 million, driven by growth in recurring and procedure revenue.
• The company placed 10 ALLY systems, bringing its global installed base to about 445 systems, while procedure volume rose 13% and U.S. market share reached 24.1%. Adjusted EBITDA hit a record $3.6 million.
• Shares rose 27.9% to $8.04, although cash declined to $13.6 million and management expects higher operating expenses and seasonal procedure weakness. Analysts maintain a mixed outlook, with an average “Hold” rating and a $9.50 price target.

LENSAR (NASDAQ:LNSR - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.26, Zacks reports. LENSAR had a net margin of 50.94% and a negative return on equity of 183.19%.

Here are the key takeaways from LENSAR's conference call:

• Q2 revenue increased 18% year over year to $16.5 million, while recurring revenue rose 20% to $13.7 million and procedure revenue grew 23% to $10.2 million.
• LENSAR placed 10 ALLY systems during the quarter, expanding the global installed base to approximately 445 systems, with 13 ALLY systems in backlog; procedure volume increased 13% to 58,682 and U.S. procedure market share reached 24.1%.
• The company reported its strongest adjusted EBITDA performance to date at $3.6 million, supported by revenue growth, a greater mix of recurring revenue, and lower expenses; gross margin was 52% excluding a $1.1 million tariff refund.
• Cash and equivalents declined to $13.6 million from $18 million at year-end 2025, and management expects operating expenses to rise toward historical levels as it increases commercial investment, creating potential variability in EBITDA over the next several quarters.
• Management cautioned that third-quarter cataract procedure volumes are historically lower because of seasonal holidays and vacations, while rebuilding overseas distributor relationships is expected to take several quarters.

LENSAR Stock Up 27.9%

Shares of NASDAQ:LNSR traded up $1.75 during trading on Thursday, hitting $8.04. 1,822,055 shares of the company were exchanged, compared to its average volume of 93,640. LENSAR has a 1-year low of $4.95 and a 1-year high of $12.96. The company has a market capitalization of $98.79 million, a P/E ratio of -13.74 and a beta of 0.89. The business's 50 day moving average is $5.79 and its 200-day moving average is $7.40.

Institutional Investors Weigh In On LENSAR

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in LENSAR by 129.0% in the third quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company's stock valued at $25,000 after purchasing an additional 1,131 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of LENSAR by 584.3% during the second quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company's stock worth $62,000 after purchasing an additional 3,991 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of LENSAR in the second quarter valued at approximately $68,000. New York State Common Retirement Fund acquired a new position in shares of LENSAR in the second quarter valued at approximately $105,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in LENSAR in the 3rd quarter valued at approximately $125,000. Institutional investors own 40.15% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wall Street Zen downgraded LENSAR from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. BTIG Research lifted their target price on LENSAR from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of LENSAR in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $9.50.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source